BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 33301467)

  • 1. Preparation of nanoliposomes containing HER2/neu (P5+435) peptide and evaluation of their immune responses and anti-tumoral effects as a prophylactic vaccine against breast cancer.
    Naghibi L; Yazdani M; Momtazi-Borojeni AA; Razazan A; Shariat S; Mansourian M; Arab A; Barati N; Arabsalmani M; Abbasi A; Saberi Z; Badiee A; Jalali SA; Jaafari MR
    PLoS One; 2020; 15(12):e0243550. PubMed ID: 33301467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. P5 HER2/neu-derived peptide conjugated to liposomes containing MPL adjuvant as an effective prophylactic vaccine formulation for breast cancer.
    Shariat S; Badiee A; Jalali SA; Mansourian M; Yazdani M; Mortazavi SA; Jaafari MR
    Cancer Lett; 2014 Dec; 355(1):54-60. PubMed ID: 25224570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A nano-liposome vaccine carrying E75, a HER-2/neu-derived peptide, exhibits significant antitumour activity in mice.
    Arab A; Behravan J; Razazan A; Gholizadeh Z; Nikpoor AR; Barati N; Mosaffa F; Badiee A; Jaafari MR
    J Drug Target; 2018 Apr; 26(4):365-372. PubMed ID: 28972792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stimulation of Tumor-Specific Immunity by p5 HER-2/neu Generated Peptide Encapsulated in Nano-liposomes with High Phase Transition Temperature Phospholipids.
    Yazdani M; Jalali SA; Badiee A; Shariat S; Mansourian M; Arabi L; Abbasi A; Saberi Z; Jaafari MR
    Curr Drug Deliv; 2017; 14(4):492-502. PubMed ID: 27411392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. P435 HER2/neu-derived peptide conjugated to liposomes containing DOPE as an effective prophylactic vaccine formulation for breast cancer.
    Farzad N; Barati N; Momtazi-Borojeni AA; Yazdani M; Arab A; Razazan A; Shariat S; Mansourian M; Abbasi A; Saberi Z; Badiee A; Jalali SA; Jaafari MR
    Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):665-673. PubMed ID: 30829072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conjugated nanoliposome with the HER2/neu-derived peptide GP2 as an effective vaccine against breast cancer in mice xenograft model.
    Razazan A; Behravan J; Arab A; Barati N; Arabi L; Gholizadeh Z; Hatamipour M; Reza Nikpoor A; Momtazi-Borojeni AA; Mosaffa F; Ghahremani MH; Jaafari MR
    PLoS One; 2017; 12(10):e0185099. PubMed ID: 29045460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Poly (I:C)-DOTAP cationic nanoliposome containing multi-epitope HER2-derived peptide promotes vaccine-elicited anti-tumor immunity in a murine model.
    Alipour Talesh G; Ebrahimi Z; Badiee A; Mansourian M; Attar H; Arabi L; Jalali SA; Jaafari MR
    Immunol Lett; 2016 Aug; 176():57-64. PubMed ID: 27260485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MPL nano-liposomal vaccine containing P5 HER2/neu-derived peptide pulsed PADRE as an effective vaccine in a mice TUBO model of breast cancer.
    Zamani P; Navashenaq JG; Nikpoor AR; Hatamipour M; Oskuee RK; Badiee A; Jaafari MR
    J Control Release; 2019 Jun; 303():223-236. PubMed ID: 30999007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanoliposomal vaccine containing long multi-epitope peptide E75-AE36 pulsed PADRE-induced effective immune response in mice TUBO model of breast cancer.
    Zamani P; Teymouri M; Nikpoor AR; Navashenaq JG; Gholizadeh Z; Darban SA; Jaafari MR
    Eur J Cancer; 2020 Apr; 129():80-96. PubMed ID: 32145473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effective induction of anti-tumor immunity using p5 HER-2/neu derived peptide encapsulated in fusogenic DOTAP cationic liposomes co-administrated with CpG-ODN.
    Mansourian M; Badiee A; Jalali SA; Shariat S; Yazdani M; Amin M; Jaafari MR
    Immunol Lett; 2014 Nov; 162(1 Pt A):87-93. PubMed ID: 25086399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanoliposomes carrying HER2/neu-derived peptide AE36 with CpG-ODN exhibit therapeutic and prophylactic activities in a mice TUBO model of breast cancer.
    Barati N; Nikpoor AR; Razazan A; Mosaffa F; Badiee A; Arab A; Gholizadeh Z; Behravan J; Jaafari MR
    Immunol Lett; 2017 Oct; 190():108-117. PubMed ID: 28736158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting of the non-mutated tumor antigen HER2/neu to mature dendritic cells induces an integrated immune response that protects against breast cancer in mice.
    Wang B; Zaidi N; He LZ; Zhang L; Kuroiwa JM; Keler T; Steinman RM
    Breast Cancer Res; 2012 Mar; 14(2):R39. PubMed ID: 22397502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preparation of nanoliposomes linked to HER2/neu-derived (P5) peptide containing MPL adjuvant as vaccine against breast cancer.
    Rastakhiz S; Yazdani M; Shariat S; Arab A; Momtazi-Borojeni AA; Barati N; Mansourian M; Amin M; Abbasi A; Saberi Z; Jalali SA; Badiee A; Jaafari MR
    J Cell Biochem; 2019 Feb; 120(2):1294-1303. PubMed ID: 30378147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exosomal pMHC-I complex targets T cell-based vaccine to directly stimulate CTL responses leading to antitumor immunity in transgenic FVBneuN and HLA-A2/HER2 mice and eradicating trastuzumab-resistant tumor in athymic nude mice.
    Wang L; Xie Y; Ahmed KA; Ahmed S; Sami A; Chibbar R; Xu Q; Kane SE; Hao S; Mulligan SJ; Xiang J
    Breast Cancer Res Treat; 2013 Jul; 140(2):273-84. PubMed ID: 23881522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of tumor-specific immunity by multi-epitope rat HER2/neu-derived peptides encapsulated in LPD Nanoparticles.
    Jalali SA; Sankian M; Tavakkol-Afshari J; Jaafari MR
    Nanomedicine; 2012 Jul; 8(5):692-701. PubMed ID: 22024191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preparation and characterization of different liposomal formulations containing P5 HER2/neu-derived peptide and evaluation of their immunological responses and antitumor effects.
    Shariat S; Badiee A; Amir Jalali S; Mansourian M; Alireza Mortazavi S; Reza Jaafari M
    Iran J Basic Med Sci; 2015 May; 18(5):506-13. PubMed ID: 26124938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cytotoxic activity of spleen lymphocytes in BALB/c mice immunized by HSP110-HER2/neu ICD].
    Han D; Xu H; Yan WQ
    Zhonghua Zhong Liu Za Zhi; 2012 Jan; 34(1):11-4. PubMed ID: 22490848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effective induction of CD8+ T-cell response using CpG oligodeoxynucleotides and HER-2/neu-derived peptide co-encapsulated in liposomes.
    Li WM; Dragowska WH; Bally MB; Schutze-Redelmeier MP
    Vaccine; 2003 Jul; 21(23):3319-29. PubMed ID: 12804863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generation of populations of antigen-specific cytotoxic T cells using DCs transfected with DNA construct encoding HER2/neu tumor antigen epitopes.
    Kuznetsova M; Lopatnikova J; Khantakova J; Maksyutov R; Maksyutov A; Sennikov S
    BMC Immunol; 2017 Jun; 18(1):31. PubMed ID: 28633645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunoliposomes bearing lymphocyte activation gene 3 fusion protein and P5 peptide: A novel vaccine for breast cancer.
    Mohammadian Haftcheshmeh S; Zamani P; Mashreghi M; Nikpoor AR; Tavakkol-Afshari J; Jaafari MR
    Biotechnol Prog; 2021 Mar; 37(2):e3095. PubMed ID: 33118322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.